Technology
GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree
Adrià Calatayud·Wall Street Journal·October 27, 2026
EXCLUSIVE: The U.K. drugmaker currently has five approved cancer medicines and a clinical-stage portfolio of about 15 assets.
Read the full story at Wall Street Journal →